Concepts (76)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 10 | 2020 | 155 | 2.380 |
Why?
|
| Brachytherapy | 6 | 2020 | 24 | 2.070 |
Why?
|
| Yttrium Radioisotopes | 8 | 2020 | 10 | 1.940 |
Why?
|
| Microspheres | 9 | 2011 | 44 | 0.900 |
Why?
|
| Embolization, Therapeutic | 4 | 2009 | 86 | 0.680 |
Why?
|
| Hepatic Artery | 3 | 2010 | 14 | 0.520 |
Why?
|
| Radiopharmaceuticals | 3 | 2018 | 93 | 0.480 |
Why?
|
| Liver | 4 | 2010 | 484 | 0.470 |
Why?
|
| Radiometry | 3 | 2011 | 40 | 0.460 |
Why?
|
| Models, Cardiovascular | 1 | 2009 | 32 | 0.340 |
Why?
|
| Eye Neoplasms | 1 | 2009 | 3 | 0.340 |
Why?
|
| Quality Control | 1 | 2008 | 44 | 0.300 |
Why?
|
| Melanoma | 1 | 2009 | 164 | 0.300 |
Why?
|
| Resins, Synthetic | 1 | 2007 | 1 | 0.300 |
Why?
|
| Radiosurgery | 2 | 2019 | 356 | 0.240 |
Why?
|
| Yttrium | 3 | 2010 | 3 | 0.180 |
Why?
|
| Health Physics | 2 | 2011 | 4 | 0.180 |
Why?
|
| Radiotherapy Dosage | 3 | 2009 | 101 | 0.170 |
Why?
|
| Positron-Emission Tomography | 2 | 2011 | 163 | 0.170 |
Why?
|
| Hemangioblastoma | 1 | 2019 | 4 | 0.170 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2019 | 5 | 0.160 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 11 | 0.160 |
Why?
|
| Humans | 12 | 2020 | 32114 | 0.160 |
Why?
|
| Quality Assurance, Health Care | 2 | 2011 | 72 | 0.160 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 16 | 0.150 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 60 | 0.150 |
Why?
|
| Nervous System Neoplasms | 1 | 2017 | 8 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 1328 | 0.140 |
Why?
|
| United States | 3 | 2011 | 3976 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 919 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2019 | 3306 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2019 | 780 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2019 | 3510 | 0.110 |
Why?
|
| Computer Simulation | 2 | 2010 | 220 | 0.100 |
Why?
|
| Angiography | 1 | 2011 | 80 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 408 | 0.090 |
Why?
|
| Neoplasms | 1 | 2018 | 728 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 112 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2011 | 164 | 0.090 |
Why?
|
| Liver Circulation | 1 | 2009 | 7 | 0.090 |
Why?
|
| Israel | 1 | 2009 | 3 | 0.090 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2009 | 19 | 0.080 |
Why?
|
| Injections, Intra-Articular | 1 | 2009 | 16 | 0.080 |
Why?
|
| Europe | 1 | 2009 | 82 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2010 | 155 | 0.080 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2009 | 9 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 104 | 0.080 |
Why?
|
| Adult | 5 | 2019 | 9380 | 0.080 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 13 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2009 | 76 | 0.080 |
Why?
|
| Nuclear Medicine | 1 | 2008 | 1 | 0.080 |
Why?
|
| Radiology, Interventional | 1 | 2008 | 5 | 0.080 |
Why?
|
| Radiation Oncology | 1 | 2008 | 10 | 0.080 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2008 | 28 | 0.080 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2007 | 18 | 0.070 |
Why?
|
| Middle Aged | 5 | 2019 | 11839 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2008 | 129 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2265 | 0.060 |
Why?
|
| Male | 6 | 2019 | 19217 | 0.060 |
Why?
|
| Female | 6 | 2019 | 20015 | 0.060 |
Why?
|
| Aged | 4 | 2017 | 10314 | 0.060 |
Why?
|
| Time Factors | 1 | 2009 | 2151 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 3990 | 0.040 |
Why?
|
| Hearing Tests | 1 | 2017 | 13 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2017 | 355 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 7542 | 0.030 |
Why?
|
| Mice | 1 | 2018 | 2484 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2009 | 34 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 60 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 84 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2008 | 31 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2007 | 23 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 134 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 220 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 877 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 633 | 0.020 |
Why?
|